<DOC>
	<DOCNO>NCT00574236</DOCNO>
	<brief_summary>Primary objective determine effectiveness combination bortezomib doxorubicin patient metastatic breast cancer . The trial format single arm Phase II design wherein patient treat bortezomib IV day 1 , 4 , 8 , 11 doxorubicin IV day 1 8 21-day cycle .</brief_summary>
	<brief_title>Phase II Trial Bortezomib Doxorubicin Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Cytologically histologically confirm metastatic breast cancer Measurable evaluable disease Age &gt; 18 , PS 0,1,2 MUGA &gt; 45 % Received one few chemotherapy investigational regimen metastatic disease , limit number prior hormonal therapy . May single agent Herceptin and/or Herceptin plus singleagent chemotx . Must meet designate laboratory criterion within 14 day enrollment Doxorubicin metatstatic disease . Pregnant lactating . Active infection , myocardial infarction within 2 month enrollment . Investigational drug within 14 day enrollment . Chemotherapy , radiotherapy , hormonal therapy investigational therapy within 4 week enrollment . Neuropathy &gt; grade 2 . Active brain mets . Hypersensitivity bortezomib , boron , mannitol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>